Spur RST: Maximizing BTK CLTI Treatment Outcomes
Published: 07 November 2024
-
Views:
41
-
Likes:
7
-
Views:
41
-
Likes:
7
Overview
Join Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, DE), Prof Thomas Zeller (University Heart Centre Freiburg-Bad Krozingen, DE) and Prof Andrej Schmidt (University-Clinic Leipzig, DE) as they delve into the Spur Peripheral Retrievable Scaffold System, mode of action for Spur RST (Retrievable Scaffold Therapy) in conjunction with the use of a DCB and the acute and most relevant 6, 12 and 24 month clinical endpoint outcomes that have an impact on a patient well-being. Additionally, they address the potential to improve and challenge today’s BTK endovascular treatment where POBA is still standard of care.
The information presented and the device featured is CE Mark approved for use in the EU. The Spur is indicated for treatment of de novo or restenotic infrapopliteal lesions, with reference vessel diameters ranging from 2.5 – 4.5mm, prior to treatment with a commercially available drug coated balloon.
Learning Objectives
- Learn why Spur RST is an optimal lesion preparation device in CLTI patients with non-healing wounds and severely diseased BTK vessels
- Understand the unique differences when comparing the Spur System to other lesion preparation and plaque modification devices
- Recall the clinical benefits of using the Spur System followed by DCB when compared to traditional treatment options for BTK CLTI
Target Audience
- Endovascular Interventionalists
- Vascular Surgeons
- Interventional Radiologists
- Angiologists
- Interventional Cardiologists
More from this programme
Part 1
Welcome and Introduction to Spur RST
Part 2
Spur RST vs. Conventional Infrapopliteal CLTI Treatment Options
Part 3
The Spur System for Effective Lesion Preparation Addressing the Below-the-Knee Vascular Challenges
Part 4
Discussion and Audience Q&A
| 1 session | |
| Discussion and Audience Q&A | Watch now |
Faculty Biographies
Michael Lichtenberg
Chief Medical Officer and Director of the Angiology Department and Vascular Center
Michael Lichtenberg, MD, FESC is the Chief Medical Officer and Director of the Angiology Department and Vascular Center at the Arnsberg Clinic in Arnsberg, Germany.
Dr Lichtenberg earned his medical degree from the Heinrich-Heine Medical University of Dusseldorf, and also studied at the Tulane University School of Medicine in New Orleans, Louisiana and the Texas Heart Institute in Houston, Texas.
As esteemed Interventional Angiologist with 20 years of experience in endovascular interventions, Dr Lichtenberg was elected to serve as Managing Director of the German Society for Angiology in 2017. In 2019, he was elected to serve as the society’s President.
Dr Lichtenberg’s areas of clinical interest include deep venous intervention, peripheral artery disease, peripheral thrombosis and atherosclerosis.
In addition to his day-to-day work in interventional care, his main interest is the evaluation of new devices, techniques and procedures for the intervention of…
Thomas Zeller
Head of the Department of Angiology
Prof Thomas Zeller is head of the Department of Angiology at University Heart Centre Freiburg-Bad Krozingen, Bad Krozingen, DE.
Prof Zeller's key interests include diagnostic and therapy of renal artery stenosis, optimisation of endovascular therapy methods of peripheral arterial occlusive disease and optimisation of non-invasive diagnostic methods in vascular medicine.
Andrej Schmidt
Interventional Cardiologist
Prof Andrej Schmidt is senior interventionalist at the University-Clinic Leipzig. He earned his degree in medicine from Freie Universitat Berlin and completed his training as an angiologist and cardiologist at the University of Dresen Carl Gustav Carus and the Heart Center at the University of Erlangen.